JP2022517174A5 - - Google Patents

Info

Publication number
JP2022517174A5
JP2022517174A5 JP2021535718A JP2021535718A JP2022517174A5 JP 2022517174 A5 JP2022517174 A5 JP 2022517174A5 JP 2021535718 A JP2021535718 A JP 2021535718A JP 2021535718 A JP2021535718 A JP 2021535718A JP 2022517174 A5 JP2022517174 A5 JP 2022517174A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
raav
composition according
sequence
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517174A (ja
JP7660062B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067872 external-priority patent/WO2020132455A1/en
Publication of JP2022517174A publication Critical patent/JP2022517174A/ja
Publication of JP2022517174A5 publication Critical patent/JP2022517174A5/ja
Application granted granted Critical
Publication of JP7660062B2 publication Critical patent/JP7660062B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535718A 2018-12-21 2019-12-20 導入遺伝子発現のdrg特異的低減のための組成物 Active JP7660062B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862783956P 2018-12-21 2018-12-21
US62/783,956 2018-12-21
US201962924970P 2019-10-23 2019-10-23
US62/924,970 2019-10-23
US201962934915P 2019-11-13 2019-11-13
US62/934,915 2019-11-13
PCT/US2019/067872 WO2020132455A1 (en) 2018-12-21 2019-12-20 Compositions for drg-specific reduction of transgene expression

Publications (3)

Publication Number Publication Date
JP2022517174A JP2022517174A (ja) 2022-03-07
JP2022517174A5 true JP2022517174A5 (cg-RX-API-DMAC7.html) 2022-12-27
JP7660062B2 JP7660062B2 (ja) 2025-04-10

Family

ID=71100588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535718A Active JP7660062B2 (ja) 2018-12-21 2019-12-20 導入遺伝子発現のdrg特異的低減のための組成物

Country Status (16)

Country Link
US (1) US20210077553A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908326A4 (cg-RX-API-DMAC7.html)
JP (1) JP7660062B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210107037A (cg-RX-API-DMAC7.html)
CN (1) CN113646005A (cg-RX-API-DMAC7.html)
BR (1) BR112021011143A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123600A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001624A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008538A2 (cg-RX-API-DMAC7.html)
IL (1) IL284185B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210160A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007600A (cg-RX-API-DMAC7.html)
PE (1) PE20211581A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551341A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105907QA (cg-RX-API-DMAC7.html)
WO (1) WO2020132455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223232A1 (en) 2019-04-29 2020-11-05 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
JP7715640B2 (ja) 2019-05-03 2025-07-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異染性白質ジストロフィーの治療に有用な組成物
BR112022011916A2 (pt) 2019-12-19 2022-09-06 Univ Pennsylvania Composições para tratar a ataxia de friedreich
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
IL298138A (en) * 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
WO2022015715A1 (en) 2020-07-13 2022-01-20 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
AU2021356684A1 (en) * 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2022082109A1 (en) 2020-10-18 2022-04-21 The Trustees Of The University Of Pennsylvania Improved adeno-associated virus (aav) vector and uses therefor
WO2022094078A1 (en) 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
EP4274592A4 (en) * 2021-01-11 2025-03-19 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240175050A1 (en) * 2021-03-19 2024-05-30 Mayo Foundation For Medical Education And Research Methods and materials for treating propionic acidemia
EP4323531A1 (en) 2021-04-12 2024-02-21 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
AU2022262771A1 (en) 2021-04-23 2023-11-02 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
CN118043468A (zh) * 2021-06-11 2024-05-14 分贝治疗公司 用于内耳中的细胞类型特异性基因表达的组合物和方法
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20240384298A1 (en) 2021-10-02 2024-11-21 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
KR20240100490A (ko) * 2021-10-18 2024-07-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물
AU2022388800A1 (en) * 2021-11-12 2024-06-27 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of mucopolysaccharidosis iiia
WO2023087019A2 (en) * 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
EP4433169A1 (en) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
TW202340467A (zh) 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
US20250346920A1 (en) 2022-01-25 2025-11-13 Voyager Therapeutics, Inc. Baculovirus expression system
JP2025507338A (ja) 2022-02-08 2025-03-18 ボイジャー セラピューティクス インコーポレイテッド Aavカプシドバリアント及びその使用
CA3247109A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4532515A1 (en) 2022-06-02 2025-04-09 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20250243263A1 (en) 2022-06-22 2025-07-31 Voyager Therapeutics, Inc. Tau binding compounds
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
US20260000790A1 (en) * 2022-07-08 2026-01-01 Ospedale San Raffaele S.R.L. Transgene cassettes
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
JP2025534229A (ja) * 2022-09-26 2025-10-15 エンコーデド セラピューティクス,インク. 後根神経節及び/又は肝臓における遺伝子発現を脱標的化するための要素
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024145474A2 (en) 2022-12-29 2024-07-04 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP4705324A1 (en) 2023-05-02 2026-03-11 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
IL324036A (en) 2023-05-03 2025-12-01 Voyager Therapeutics Inc Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2024229389A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2026515970A (ja) 2023-05-04 2026-05-19 ボイジャー セラピューティクス インコーポレイテッド Aavカプシドバリアント及びその使用
EP4711461A1 (en) * 2023-05-12 2026-03-18 Genecombio Ltd. Viral vector carrying smn gene expression cassette and use thereof
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
WO2025122530A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025122644A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease
WO2025147436A1 (en) 2024-01-03 2025-07-10 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025217023A1 (en) * 2024-04-08 2025-10-16 The Trustees Of The University Of Pennsylvania Gene therapy for gangliosidosis type 2 (gm2)
WO2025235734A2 (en) 2024-05-09 2025-11-13 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2026010722A1 (en) 2024-07-03 2026-01-08 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2026028089A1 (en) 2024-07-29 2026-02-05 Novartis Ag Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2026101977A1 (en) 2024-11-06 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026151888A1 (en) 2025-01-08 2026-07-16 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099196A1 (en) * 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
US20100286044A1 (en) * 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
EP2520649A3 (en) * 2007-11-23 2013-02-20 Panagene, Inc. MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
DK2561073T3 (en) * 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
JOP20190200A1 (ar) * 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي

Similar Documents

Publication Publication Date Title
JP2023526310A5 (cg-RX-API-DMAC7.html)
JP6495273B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
KR102527259B1 (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
JP2023523237A (ja) snRNA構成要素を使用する組成物及び方法
KR20220004680A (ko) 신규 aav 캡시드 및 이를 포함하는 조성물
JP2021502060A5 (cg-RX-API-DMAC7.html)
JP2021500049A (ja) 神経変性疾患の遺伝子治療
JP2019519219A5 (cg-RX-API-DMAC7.html)
WO2015196179A1 (en) Methods of packaging multiple adeno-associated virus vectors
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2022553406A5 (cg-RX-API-DMAC7.html)
US20250136994A1 (en) Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
AU2021305575C1 (en) Novel intron fragments
WO2020037161A1 (en) Combination therapy for spinal muscular atrophy
WO2022098923A1 (en) Enhancement of predictable and template-free gene editing by the association of cas with dna polymerase
JP2021525531A5 (cg-RX-API-DMAC7.html)
JP2023551254A5 (cg-RX-API-DMAC7.html)
Snyder et al. Viral vector-mediated gene transfer for CNS disease
WO2024254242A2 (en) Rnai targeting kif1a missense mutations for treatment of kif1a associated neurological disorder
JP7575761B2 (ja) 核酸封入aav中空粒子の製造方法
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
US20240325454A1 (en) Genomic editing of rbm20 mutations
JP2024546578A5 (cg-RX-API-DMAC7.html)
US20240409945A1 (en) RNAi TARGETING PPP2R5D MISSENSE MUTATIONS FOR TREATMENT OF JORDAN’S SYNDROME